Background: Thymic carcinomas are rare tumors of the anterior mediastinum. These tumors are distinct thymic neoplasms that differ from their more common counterpart, thymoma. As opposed to thymomas, thymic carcinomas are histologically malignant neoplasms with a clinical course that tends to be much more aggressive than that of patients with thymoma.
Methods: Between 1984 and 1990, five patients with thymic carcinoma treated with cisplatin-based combination chemotherapy were seen at Indiana University Hospital. These patients' diagnoses, courses, and treatments were reviewed.
Results: Three patients responded (two completely) to cisplatin-based chemotherapy.
Conclusions: This form of chemotherapy merits additional study in such patients, and our experience indicates that at least some will have clinically meaningful responses. The optimum regimen is unclear, but would contain cisplatin and probably should be similar to that used in germ cell tumors.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/1097-0142(19930215)71:4<1219::aid-cncr2820710408>3.0.co;2-b | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Clinical case : Prevascular mediastinal mass].
Rev Med Liege
January 2025
Service de Radiodiagnostic, CHU Liège, Belgique.
In the event of a prevascular mediastinal mass, knowledge of the anatomy and content of the mediastinum is an essential prerequisite to establish a differential diagnosis. The «4T» rule is applicable because it is a simple and effective mnemonic. It groups together; thyroid goiter, terrible lymphoma, teratoma and thymoma.
View Article and Find Full Text PDFIncidence, characteristics, and comorbidities of a complete unselected Danish cohort of patients with thymic epithelial tumors.
Acta Oncol
January 2025
Department of Oncology, Copenhagen University Hospital, Copenhagen, Denmark.
Background And Purpose: We report the incidence, characteristics, and comorbidities of the complete unselected Danish cohort of patients with thymic epitheliums (TETs), which may serve as evidence for guiding treatment, surveillance, and counselling of TET patients.
Patients And Methods: All patients diagnosed with TETs from January 1st, 2015, to December 31st, 2020, were identified using the Danish Pathology Data Registry. Data on patient characteristics, comorbidities, and tumor histology were collected from electronic medical records available for all patients.
Myasthenia Gravis as a Paraneoplastic Manifestation of Renal Cell Carcinoma: More Than a Coincidence?
Ann Neurosci
January 2025
Department of Neurology, Pushpagiri Institute of Medical Sciences and Research Centre, Thiruvalla, Kerala, India.
Background: Myasthenia gravis is an autoimmune neuromuscular disease primarily caused by autoantibodies against nicotinic acetylcholine receptors (AChRs) at the neuromuscular junction. However, extrathymic malignancies need to be considered in the elderly population.
Purpose: Although thymic malignancy is the most common tumour association, several extrathymic malignancies complicated with myasthenia gravis have been reported.
Response to comment on "Too early to be different? A multi-institutional study with 30-year follow-up for prognostic factors of completely resected early stage thymoma".
J Formos Med Assoc
January 2025
Division of Thoracic Surgery, Department of Surgery, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan; Division of Trauma and Acute Care Surgery, Department of Surgery, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan. Electronic address:
Prognostic Factors After Resection for Thymoma Distant Recurrences.
J Thorac Oncol
January 2025
Thoracic Surgery, Fondazione Policlinico Universitario A. Gemelli stituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, Italy; Università Cattolica del Sacro Cuore, Rome, Italy.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!